Upsher-Smith Laboratories, LLC has launched of Vigadrone (vigabatrin) for Oral Solution, 500 mg, a fully substitutable, AA-rated generic version of Sabril powder for oral solution.* The product was approved by the U.S. Food and Drug Administration (FDA) on June 21, 2018. The Vigabatrin powder market had U.S. sales of approximately $333 million for the 12 months ending December 31, 2017, according…
Upsher-Smith Launches Doxazosin Tablets, USP
Upsher-Smith Laboratories announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg, and 8 mg. The product was approved by the FDA on April 17, 2018. Upsher-Smith’s Doxazosin Tablets are an AB-rated generic version of the branded product, Cardura (doxazosin mesylate tablets). The doxazosin tablet market had U.S. sales of approximately $51.2 millionfor the 12…